Cancer BiologybioRxivPreprint
Pharmacological control of CAR T cells through CRISPR-driven rapamycin resistance
Sébastien Levesque, Gillian A. Carleton, Victoria Duque…·Yannick Doyon
This study develops a CRISPR-based method to create rapamycin-resistant CAR-T cells, enabling pharmacological control of their activity in cancer therapy.